Anne Gomez-Brouchet
Overview
Explore the profile of Anne Gomez-Brouchet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nham T, Guiho R, Brion R, Amiaud J, Le Royer B, Gomez-Brouchet A, et al.
Oral Dis
. 2024 Feb;
30(7):4209-4219.
PMID: 38376129
Objectives: Investigation of the therapeutic effect of zoledronic acid (ZA) in a preclinical model of jaw osteosarcoma (JO). Materials And Methods: The effect of 100 μg/kg ZA administered twice a...
2.
Gazda P, Baujat B, Sarini J, Gomez-Brouchet A, Philouze P, Moya-Plana A, et al.
Eur J Surg Oncol
. 2024 Jan;
50(2):107315.
PMID: 38219696
Introduction: Laryngeal chondrosarcoma (LCS) is a rare tumor of slow evolution whose treatment is poorly codified. For a long time, a radical treatment by total laryngectomy (TL) was proposed. More...
3.
Marques Da Costa M, Droit R, Khneisser P, Gomez-Brouchet A, Adam-de-Beaumais T, Nolla M, et al.
Front Oncol
. 2023 Jun;
13:1166063.
PMID: 37377921
Osteosarcoma is a rare bone cancer in adolescents and young adults with a dismal prognosis because of metastatic disease and chemoresistance. Despite multiple clinical trials, no improvement in outcome has...
4.
Paillasse M, Esquerre M, Bertrand F, Poussereau-Pomie C, Pichery M, Visentin V, et al.
Cancer Res Commun
. 2023 Mar;
2(11):1504-1519.
PMID: 36970050
Significance: The VEGFR-3 inhibitor EVT801 demonstrates superior selectivity and toxicity profile than other VEGFR-3 tyrosine kinase inhibitors. EVT801 showed potent antitumor effects in VEGFR-3-positive tumors, and tumors with VEGFR-3-positive microenvironments...
5.
Bertin H, Peries S, Amiaud J, Van Acker N, Perrot B, Bouvier C, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831348
Background-The purpose of this study was to investigate the bone resorption, as well as the vascular and immune microenvironment, of jaw osteosarcomas (JO) and to correlate these features with patient...
6.
Chaves-Almagro C, Auriau J, Dortignac A, Clerc P, Lulka H, Deleruyelle S, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142542
Despite decades of effort in understanding pancreatic ductal adenocarcinoma (PDAC), there is still a lack of innovative targeted therapies for this devastating disease. Herein, we report the expression of apelin...
7.
Poumeaud F, Duval M, Gambart M, Dierickx L, Abbo O, Hangard G, et al.
Pediatr Blood Cancer
. 2022 Jun;
70(1):e29834.
PMID: 35731232
No abstract available.
8.
Crenn V, Amiaud J, Gomez-Brouchet A, Potiron V, Gouin F, Rosset P, et al.
Am J Cancer Res
. 2022 May;
12(4):1843-1854.
PMID: 35530297
Predicting a response of osteosarcoma patients to chemotherapy, such as doxorubicin or high-dose methotrexate cocktail, remains a challenge in the clinic. Moreover, the prognostic value of currently used necrosis analysis...
9.
Nazon C, Pierrevelcin M, Willaume T, Lhermitte B, Weingertner N, Di Marco A, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326631
Background: Osteosarcomas (OTS) represent the most common primary bone cancer diagnosed in adolescents and young adults. Despite remarkable advances, there are no objective molecular or imaging markers able to predict...
10.
Krantschenko E, Khayat P, Siegfried A, Van Acker N, Gomez-Brouchet A
Ann Pathol
. 2022 Feb;
42(3):208-213.
PMID: 35184892
No abstract available.